Emma Urlings: A Novel Thrombin Generation Assay for Sensitive Emicizumab Monitoring
Emma Urlings, Ph.D. Candidate at Maastricht UMC+, shared on LinkedIn about a recent article she and her colleagues co-authored, published in RPTH, adding:
”Our manuscript is now published in Research and Practice in Thrombosis and Haemostasis!
‘Intrinsic activated thrombin generation for treatment efficacy and monitoring of octocog alfa and emicizumab in severe hemophilia A’
Conventional laboratory assays fall short for monitoring emicizumab in severe hemophilia A.
We developed PPP Reagent INT, a novel intrinsic pathway thrombin generation assay (TGA) reagent, and showed it is sixfold more sensitive to emicizumab levels than tissue factor-based reagents in patient plasma, with sensitivity down to very low concentration ranges relevant for dose-reduction strategies.
The choice of TGA reagent should match the mechanism of action of the treatment.
With Floor Heubel-Moenen, René van Oerle, Dave Hellenbrand, Paola van der Meijden, Tilman Hackeng, Hugo Cate, Magdolna Nagy, Henskens Yvonne and Henri Spronk.”
Title: Intrinsic activated thrombin generation for treatment efficacy and monitoring of octocog alfa and emicizumab in severe hemophilia A
Authors: Emma H. Urlings, Floor C.J.I. Heubel-Moenen, René van Oerle, Dave L.S. Hellenbrand, Paola E.J. van der Meijden, Tilman M. Hackeng, Hugo ten Cate, Magdolna Nagy, Yvonne M.C. Henskens, Henri M.H. Spronk
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 5, 2026, 15:34Ney Carter Borges: Low-Dose Rivaroxaban in Advanced Chronic Kidney Disease – Lessons From the TRACK Trial
-
Jun 5, 2026, 15:29Nethuki Kulasinghe: Sequential Anticoagulation in Postpartum Iliocaval Thrombosis With Submassive PE and HIT
-
Jun 5, 2026, 15:23Michelle Leona Cecil: Microhealth – Digital Health Platform for Bleeding Disorders Community
-
Jun 5, 2026, 15:23Claudia Rizk: Collaborative Endovascular Intervention Enables Successful Treatment of Acute Limb Ischemia
-
Jun 5, 2026, 15:10Amna Ahmed: A Step Closer to Solving Bleeding Disorders of Unknown Cause
-
Jun 5, 2026, 14:44Jan T. Kielstein: Bleeding Risk Outweighs Potential Benefits of Rivaroxaban in CKD Patients
-
Jun 5, 2026, 14:31Arwa Z. Al-Riyami: Honored to Serve as ISBT EMR Regional Director
-
Jun 5, 2026, 14:25Bhabajit Patnaik: The End of One Chapter, the Beginning of Another
-
Jun 5, 2026, 14:19Tareq Abadl: The Science of Blood Component Separation and Targeted Transfusion Care